Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

IMPORTANCE: Nivolumab plus ipilimumab is superior to platinum-based chemotherapy in treatment-naive advanced non–small cell lung cancer (NSCLC). Nivolumab is superior to docetaxel in advanced pretreated NSCLC. OBJECTIVE: To determine whether the addition of ipilimumab to nivolumab improves survival...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:JAMA Oncol
Main Authors: Gettinger, Scott N., Redman, Mary W., Bazhenova, Lyudmila, Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tavernier, Susan S., Yu, Hui, Unger, Joseph M., Minichiello, Katherine, Highleyman, Louise, Papadimitrakopoulou, Vassiliki A., Kelly, Karen, Gandara, David R., Herbst, Roy S.
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2021
Teme:
Original Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8283667/
https://ncbi.nlm.nih.gov/pubmed/34264316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.2209
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki